| Literature DB >> 35658863 |
Hind Abdulaziz Al-Hoqail1, Mohammed T A Omar2,3, Maha Mohammed Al-Marwani2, Einas Soliman Al-Eisa2.
Abstract
BACKGROUND: Burden of breast cancer it continues to increase largely because of the aging and growth of the world population and assessment of quality of life is an important outcome measure to facilitate and improved care among breast cancer survivors, the aim of this study was to evaluate evidence of reliability, validity, and responsiveness of the Arabic version of the FACT-B + 4 questionnaire among participants with breast cancer related lymphedema (BCRL) in Saudi Arabia.Entities:
Keywords: Breast cancer-related lymphedema; FACT-B + 4; Psychometric properties; Quality of life; Reliability; Validity
Mesh:
Year: 2022 PMID: 35658863 PMCID: PMC9166420 DOI: 10.1186/s12905-022-01787-x
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.742
Hypotheses to assess construct validity
| Construct | Considering all correlation coefficients between most similarities’ subscale of the FACTB + 4 and the corresponding domains of SF-36, had moderate correlation |
|---|---|
| Known-groups validity | Patients with BCRL have: 5. A lower total score on the FACTB + 4 6. A lower score on teach subscale the FACTB than BC participants without lymphedema |
SF-36 Medical Outcomes Study 36-Item Health Survey, FACTB + 4 Functional Assessment of Cancer Therapy-Breast plus Arm morbidity version4
Sociodemographic and clinical characteristics of the participants with BCRL (n = 51) and BC without lymphedema (n = 34)
| Variables | BCRL group | BC-group |
|---|---|---|
| Age (mean ± SD) years | 53.39 ± 10.89 | 56.73 ± 3.15* |
| Marital status | ||
| Single | 2 (3.9%) | 3 (8.80%)§ |
| Married | 39 (76.50%) | 26 (76.50%) |
| Divorced | 7 (13.70%) | 3 (8.80%) |
| Widowed | 3 (5.90%) | 2 (5.90%)) |
| Education | ||
| Elementary | 21 (41.20%) | 13 (38.24%) § |
| Higher school | 15 (29.40%) | 13 (38.24%) |
| University degree | 15 (29.40%) | 8 (23.52%) |
| Family size | ||
| < 3 | 5 (9.80%) | 7 (20.60%) § |
| 3–5 | 15 (29.40%) | 10 (29.40%) |
| > 5 | 31 (60.80%) | 17 (50.00%) |
| Employment | ||
| Housewife | 36 (70.60%) | 22 (64.70%) § |
| Employment | 3 (5.9%) | 5 (14.70%) |
| Retried | 12 (23.5%) | 7 (20.60%) |
| BMI | ||
| < 30 kg/cm2 | 15 (29.40%) | 13 (38.20%) § |
| > 30 kg/cm2 | 36 (70.60%) | 21 (61.80%) |
| Breast surgery | ||
| Mastectomy | 31 (60.80%) | 15 (44.10%) § |
| Breast-conserving surgery | 20 (39.20%) | 19 (55.90%) |
| Lymphedema site | ||
| Right | 30 (58.8%) | – |
| Left | 21 (41.20%) | – |
| Lymphedema duration | ||
| < 3years | 22 (43.10%) | - |
| 3–5 years | 17 (33.30%) | - |
| > 5 years | 12 (23.50%) | - |
BC breast cancer, BCRL breast cancer related lymphedema, BMI body mass index, SD standard deviation
*Non-significant difference (P > 0.05) Mann Whitney U-test
§Non-significant difference (P > 0.05) Chi square test
Cronbach alpha, Intraclass correlation coefficient, SEM and MDC and their corresponding 95% CI for the participants with BCRL
| Subscales | Internal consistency α | FACT-B + 4 (Time 1) | FACT-B + 4 (Time 2) | ICC | 95% CI for ICC2,1 | SEM | MDC95 | 95% CI for MDC95 | |
|---|---|---|---|---|---|---|---|---|---|
| PWB (7; 0–28) | 0.84 | 19.70 ± 6.68 | 18.79 ± 5.66 | 0.50* | 0.87 | 0.76–0.93 | 2.23 | 6.18 | − 5.27 to 7.09 |
| SWB (7; 0–28) | 0.74 | 23.25 ± 5.38 | 23.12 ± 5.74 | 0.82* | 0.79 | 0.62–0.89 | 2.54 | 7.06 | − 6.65 to 7.47 |
| EWB (6; 0–24) | 0.75 | 21.05 ± 2.90 | 20.76 ± 2.83 | 0.23* | 0.87 | 0.77–0.93 | 1.03 | 2.41 | − 2.12 to 2.70 |
| FWB (7; 0–28) | 0.80 | 23.38 ± 3.75 | 23.32 ± 3.33 | 0.90* | 0.72 | 0.67–0.85 | 1.87 | 5.20 | − 5.14 to 5.26 |
| BC 10 (10; 0–40) | 0.75* | 24.35 ± 6.61 | 23.94 ± 5.69 | 0.46* | 0.86 | 0.74–0.93 | 2.31 | 6.39 | − 5.98 to 6.80 |
| ARM (5; 0–20) | 0.84 | 10.85 ± 5.39 | 10.47 ± 5.58 | 0.23* | 0.94 | 0.89–0.97 | 1.34 | 3.72 | − 4.1 to 3.34 |
| FACT-B TOI (24; 0–96) | 0.85 | 67.44 ± 13.23 | 66.05 ± 11.18 | 0.42* | 0.89 | 0.80–0.94 | 4.06 | 11.25 | − 9.87 to 12.63 |
| FACT-G (27; 0–108) | 0.87 | 87.40 ± 14.17 | 86.00 ± 12.13 | 0.37* | 0.92 | 0.84–0.96 | 3.73 | 10.34 | − 8.94 to 11.74 |
| FACT-B (37; 0–148) | 0.89 | 111.75 ± 19.09 | 109.94 ± 16.48 | 0.32* | 0.93 | 0.86–0.96 | 4.72 | 13.07 | − 11.26 to 14.88 |
| FACT-B + 4 (41; 0–164) | 0.90 | 122.23 ± 23.02 | 120.79 ± 20.52 | 0.43* | 0.94 | 0.88–0.97 | 5.34 | 14.80 | − 13.37 to 16.23 |
Cronbach’s alpha excluding item (P2), PWB physical well-being, SWB social/ family well-being, EEWB emotional well-being, FWB functional well-being, FACT-B TOI = (PWB + FWB + BCS), FACT-B + 4 = PWB + SWB + EWB + FWB + BCS + ARM, ICC intraclass correlation coefficient, CI confidence interval, SEM standard error of the measurement, MDC minimal detectable change, FACT-B + 4 Functional Assessment of Cancer Therapy-Breast plus Arm morbidity
*Non-significant P values (P > 0.05) for Wilcoxon test
Fig. 1Bland–Altman plot for the total score of the Arabic FACTB + 4 questionnaire
Correlation between the Arabic FACTB + 4 and other SF-36
| Subscales | PWB | SWB | EWB | FWB |
|---|---|---|---|---|
| Physical function | – | – | – | 0.54* |
| Role limitation due to physical health | 0.60* | – | – | |
| Role limitation due to emotional problems | – | – | 0.60* | – |
| Social functioning | – | 0.42* | – | – |
PWB physical well-being, SWB social/family well-being, EEWB emotional well-being, FWB functional well-being
*Correlations significant at the .01 level
Mean scores of the Arabic version of FACTB + 4 for participants with BCRL and breast cancer without lymphedema
| Subscales | Mean (SD) | MD (95%CI) | ||
|---|---|---|---|---|
| BCRL (n = 34) | BC without lymphedema (n = 34) | |||
| PWB (7; 0–28) | 19.70 ± 6.68 | 19.91 ± 5.75 | − .20 (− 3.22 to 2.810 | 0.89* |
| SWB (7; 0–28) | 23.25 ± 5.38 | 26.25 ± 2.84ǂǂ | − .20 (− 3.22 to 2.81) | 0.006 |
| EWB (6; 0–24) | 21.05 ± 2.90 | 21.91 ± 2.86* | .14 (− 1.25 to 1.55) | 0.83* |
| FWB (7; 0–28) | 23.38 ± 3.75 | 23.94 ± 3.69* | − .55 (− 2.26 to 1.15) | 0.51* |
| BC 10 (10; 0–40) | 24.35 ± 6.61 | 29.44 ± 5.16ǂǂ | − 5.08 (− 7.96 to − 2.20) | 0.001 |
| ARM (5; 0–20) | 10.85 ± 5.39 | 17.35 ± 4.01ǂǂ | − 6.88 (− 9.2 to − 4.54) | 0.001 |
| FACT-B TOI (24; 0–96) | 67.44 ± 13.23 | 73.29 ± 10.58ǂ | − 5.85 (− 11.65 to .05) | 0.04 |
| FACT-G (27; 0–108) | 87.40 ± 14.17 | 91.01 ± 9.41* | − 3.60 (− 9.43 to 2.21) | 0.22* |
| FACT-B (37; 0–148) | 111.75 ± 19.09 | 120.45 ± 12.55ǂ | − 8.69 (− 16.52 to − .87) | 0.03ǂ |
| FACT-B + 4 (41; 0–164) | 122.23 ± 23.02 | 137.80 ± 13.83ǂǂ | − 15.57 (− 24.77 to − 6.38) | 0.001 |
PWB physical well-being, SWB social/family well-being, EEWB emotional well-being, FWB functional well-being, FACT-B TOI = (PWB + FWB + BCS), FACT-B + 4 = PWB + SWB + EWB + FWB + BCS + ARM, FACT-B + 4 Functional Assessment of Cancer Therapy-Breast plus Arm morbidity
*Non-significant P values (P > 0.05) for Mann–Whitney U test
ǂSignificant P values (P < 0.05) for Mann–Whitney U test
ǂ ǂSignificant P values (P < 0.01) for Mann–Whitney U test
Responsiveness to change of FACT-B + 4 scores in BC participants before and after surgery
| Subscales | Pre-operative | 4 weeks post-operative | MD (95% CI) | |
|---|---|---|---|---|
| PWB (7; 0–28) | 20.85 ± 5.83 | 17.38 ± 5.45ǂ | 3.47 (0.05–6.89) | 0.04 |
| SWB (7; 0–28) | 26.18 ± 2.76 | 24.12 ± 3.87ǂ | 2.07 (0.18–3.97) | 0.03 |
| EWB (6; 0–24) | 20.57 ± 2.69 | 20.85 ± 2.92* | − .28 (− 2.19 to 1.62) | 0.75 |
| FWB (7; 0–28) | 23.52 ± 4.53 | 20.67 ± 3.76ǂ | 2.84 (0.72–4.97) | 0.01 |
| BC 10 (10; 0–40) | 29.04 ± 5.86 | 27.90 ± 4.57* | 1.14 (− 2.08 to 4.37) | 0.46 |
| ARM (5; 0–20) | 19.04 ± 2.13 | 14.46 ± 4.968ǂǂ | 4.58 (2.01–7.14) | 0.001 |
| FACT-B TOI (24; 0–96) | 73.42 ± 12.37 | 65.966 ± 10.53ǂ | 7.46 (0.47–14.46) | 0.03 |
| FACT-G (27; 0–108) | 91.13 ± 10.81 | 83.01 ± 11.44ǂ | 8.12(1.57–14.69) | 0.01 |
| FACT-B (37; 0–148) | 120.18 ± 14.95 | 110.92 ± 14.40ǂ | 9.26 (0.74–17.78) | 0.03 |
| FACT-B + 4 (41; 0–164) | 139.23 ± 15.68 | 125.36 ± 16.98ǂǂ | 13.84 (4.14–23.54) | 0.007 |
PWB physical well-being, SWB social/family well-being, EEWB emotional well-being, FWB functional well-being, FACT-B TOI = (PWB + FWB + BCS), FACT-B + 4 = PWB + SWB + EWB + FWB + BCS + ARM, FACT-B + 4 functional assessment of cancer
ǂSignificant P values (P < 0.05) for Wilcoxon test
ǂ ǂSignificant P values (P < 0.01) for Wilcoxon test
*Non-significant P values (P > 0.05) for Wilcoxon test